chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Is coughing a side effect of the vaccine?; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of COUGH (Is coughing a side effect of the vaccine?) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (Is coughing a side effect of the vaccine?). At the time of the report, COUGH (Is coughing a side effect of the vaccine?) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   No treatment information provided.
3 days after vaccination, noticed joint pain in right arm and hand. By 5 days after vaccination experienced immobilizing pan in both shoulders, hips, knees and hands.
pt recvd vax; very reddened & rt arm over the entire 1/4 lateral aspect of arm from shoulder to elbow;
I've been experiencing headaches, nausea, increased urination, vomiting, dizziness, tiredness, weakness, feeling faint, increased blood pressure and heart rate, room spinning, vertigo (BPPV), nasty taste in my mouth, and sweating. I've also experienced confusion and forgetfulness. I've felt pressure in my forehead.
Arm turned red and warm -> large area about 4 inches. Starting to fade as of 10/9/14. Pt went to the doctor, was told to wait.
Itching skin rash last 6 weeks c/w erythema multiforme.  Began on scalp and spread to arms and upper trunk.  Responded initally to steroids.
Sever Stomach pain, went to ER, they gave pain meds, check gall bladder, Cat scan on stomach, blood work
cancer; first dose over a year ago; This case was reported by a other health professional via call center representative and described the occurrence of cancer in a 70-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 31st July 2019, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than a year after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced cancer (serious criteria GSK medically significant) and incomplete course of vaccination. The patient was treated with chemotherapy, nos (Chemotherapy). On an unknown date, the outcome of the cancer and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the cancer to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient received 1st dose over a year before reporting. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The patient diagnosed with cancer (not specified) and undergoing chemotherapy. No more information could be gathered since reporter made emphasis on only wanting opinions or answers on their questions. Reporter's question was regarding safety of a second dose of Shingrix to the patient, considering chemotherapy, viability of the second dose after the longer period of validity for second dose and if it was possible and efficient to only administer one dose of Shingrix. The reporter consented to follow up.
p/vax pt broke out w/spot above eye, then hives;hives lt spot grew;tx for eczema but rash changed & cont;on hands, feet, arms, legs, face everywhere very red in color;poss drug rxn;seen by dermatologist;no one sure what it is;tx steroids;
Vaccine was administered on 04/29/20201 or 04/30/2021.  On 05/02/2021 patient was found deceased in residence.  Coroner's office will be performing autopsy.
Fevers after 10 hours of getting shot and lasting up to 27 hours after getting shot with them getting up to 102.3 and 102.8. Joint stiffness and severe muscle aches. Headache for 2 days. Metal taste when eating for 1 full day after getting shot.  Severe fatigue for 3 days.
Vaccine inadvertently placed at table giving 2nd dose Moderna vaccine. Patient may have received Vaccine instead of Moderna as second dose. Patient completed observation period without incident and was informed of event and was feeling well at that time.
General fatigue/malaise (4/1/21), muscle pain at injection site, bad headache (4/2/21 - 12:30 am) -- no treatment
Body aches; Fatigue; Headache; Chills; Fever; Redness, pain and swelling at injection site; Redness, pain and swelling at injection site; Redness, pain and swelling at injection site; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 13Apr2021 at 15:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination included levothyroxine (MANUFACTURER UNKNOWN) and loratadine (CLARITIN) from unknown date for unknown indication. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 09:00, the patient experienced redness, pain and swelling at injection site; fever; chills; headache; body aches; fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events redness, pain and swelling at injection site; fever; chills; headache; body aches; fatigue was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 15-OCT-2011, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 28-SEP-2016, the patient was treated by physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
rash; cough; This case was reported by a nurse via call center representative and described the occurrence of rash in a 73-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2019-2020 season) for prophylaxis.   The patient's past medical history included shingles.   On 23rd October 2019, the patient received the 1st dose of Shingrix (intramuscular) and Influenza vaccine Quadrivalent 2019-2020 season. On an unknown date, less than 6 months after receiving Shingrix and not applicable after receiving Influenza vaccine Quadrivalent 2019-2020 season, the patient experienced rash and cough. On an unknown date, the outcome of the rash was recovered/resolved and the outcome of the cough was unknown.   The reporter considered the rash to be related to Shingrix. It was unknown if the reporter considered the cough to be related to Shingrix and Influenza vaccine Quadrivalent 2019-2020 season.  Additional details were reported as follows: The 1st shot was given intramuscularly in his right deltoid. The flu shot [brand name unspecified] was given in his left arm at the same time. Reporter was not at home therefore the Shingrix paperwork was not available to look for the lot number or expiry date however reporter did provide the name or location of the pharmacy where the shot was administered. Caller stated that husband developed a rash on the same arm where the Shingrix was injected.  The rash was not at the injection site (deltoid) but it was down by his elbow. It resolved.  About 3 weeks ago the patient had his second shot of Shingrix.  The second injection was given intramuscularly in the left arm. He received the injection even though he had a cough at the time. (The reporter was said she does not know the cough may have been Covid-19 related as he has not been tested). The cough has since resolved. [The patient did NOT experience a rash after the second Shingrix shot].  Negative history of live shingles vaccine (Zostavax). The reporter consented to follow up. This is 1 out of 3 cases reported by the same reporter.
This spontaneous report was received from a vaccine coordinator, concerning unspecified number of patients of unknown age and gender. There were no concurrent conditions, medical history, drug reactions, allergies or concomitant medications reported. On unspecified dates, the patients were orally vaccinated with an improperly stored dose of ROTATEQ (dose, frequency, lot # and expiration date were not reported) for prophylaxis. The temperature of the ROTATEQ was between 9 °C and 22°C for a time frame of 25 hours and 48 minutes (reported as "25.8 hours") and between 0 °C and 1 °C for a time frame of 25 hours and 48 minutes (reported as "25.8 hours"). No previous temperature excursion occurred, and data logger was involved. No adverse effects were reported. This is one of three reports received from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1706USA002899: US-009507513-1706USA002898:
Patient received Moderna COVID vaccine on 4/7/22 but its expiration date was 4/6/22; This spontaneous case was reported by a medical assistant and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received Moderna COVID vaccine on 4/7/22 but its expiration date was 4/6/22) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 069H21A) for COVID-19 vaccination.     The data was unknown whether the patient ever been diagnosed or tested positive for COVID-19. Acute illness at the time of vaccination and up to one month before was none.  Concurrent medical conditions included Penicillin allergy.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Apr-2022 at 10:00 AM, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 07-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received Moderna COVID vaccine on 4/7/22 but its expiration date was 4/6/22). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received Moderna COVID vaccine on 4/7/22 but its expiration date was 4/6/22) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Weight was reported as 218 with no units. Patient had no chronic illness. No concomitant medications were reported. No treatment medications were reported. No adverse reaction to the vaccine was reported.   This case was linked to MOD-2022-538543 (Patient Link).
This spontaneous report was received from a healthcare worker concerning a patient of unknown demographics. Pertinent medical history, concurrent conditions, drug reactions or allergies were not reported. On an unknown date the patient was vaccinated with GARDASIL (dose, dose number, route, anatomical location, lot number and expiration date were unspecified). Concomitant therapies were not reported. On an unknown date the patient developed "a high risk type of HPV". The outcome of HPV infection was unknown. The relatedness between the event and GARDASIL was not reported. Additional information is not expected, no contact details were provided.
2 weeks after vaccination patient had significant nosebleed requiring packing and overnight hospitalization. He has no known bleeding disorder and not taking any anticoagulation medication. Platelet count, PT, PTT were all in normal range. Minor bleeding continue for several days after initial event.
Patient reports an anaphylactic reaction to the second Pfizer dose including his throat closing off.
Child 2 years 8 months was given dose for 36 months and up. Age of patient at time of event: 2 years 8 months.
Left upper arm started hurting at the time of the vaccination and the pain never went away or lessened in severity. The pain is also in my shoulder. Sometimes it hurts so bad, I'm unable to lift my arm to do certain things. It's been over 2 months, and the pain shows no signs of going away. My arm feels the same as it did the day I got vaccinated.
pt recv vax 13JUN96 & on 16OCT96 pt devel a generalized rash w/more than 50 lesions;
Information has been received from a pharmacist referring to a patient of unknown age and gender. Information about patient's concurrent conditions and medical history was not reported. "Greater than 5 years prior to prior to 05-NOV-2015", on an unspecified date the patient was vaccinated with a dose of PNEUMOVAX 23 (lot#/expiration date, dose and route not reported). On 05-NOV-2015 the patient was vaccinated with another dose of PNEUMOVAX 23 (dose and route not reported, lot # K009107 with expiration date 21-JAN-2016) (inappropriate schedule of vaccine administered, outside the recommendations for PNEUMOVAX 23). It was reported that the patient received the 2 doses of vaccine after 65 years old. No adverse effects were reported. This is one of two reports received from the same reporter (other linked case # 1511USA006171). Additional information is not expected because the reporter did not want to be contacted.
My white blood count went really high; The first dose was on 28Dec2020 and the Lot: EH9899. The second dose 12Jan2021 at 7am, Lot: EL1284; Extremely achy/Body aches; Chills; Back hurts so bad that she can't lay down; Sweating; The first round of the vaccine she had flu like symptoms. This time, with the second dose, it is more severe; The first round of the vaccine she had flu like symptoms. This time, with the second dose, it is more severe; This is a spontaneous report received from a contactable consumer (patient). A 30-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1284, expiry date: unknown), via an unspecified route of administration in the right arm, on 12Jan2021 07:00, at single dose, for COVID-19 immunization, in the hospital. The patient medical history and concomitant medications were not reported. The patient had no allergies. Historical vaccine included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EH9899, expiry date: unknown), via an unspecified route of administration, on 28Dec2020, for COVID-19 immunization and the patient had flu-like symptoms. The patient reported that with the first round of the vaccine, she had flu like symptoms. This time in Jan2021, with the second dose, it was more severe and if she didn't keep up with Tylenol, she was extremely achy, had chills, her back hurts so bad that she couldn't lay down, and sweating. The patient wanted to know if that was normal. The patient mentioned she called out of work for the rest of the week and left early on Tuesday. The patient stated that she had not been to the doctor at this point but when Tylenol wears off it was really ugly and would consider going. The patient stated that she was almost on septic. Her white blood count went really high on 12Jan2021 and was hospitalized from 16Jan2021. She was put on Cefepime, 2 gm per vial, gotten maybe 4 of them so far. Body aches was ongoing. Her blood work was getting better. The outcome of events white blood count went really high, extremely achy/body aches was not recovered.The outcome of other events was unknown.  Follow-up (17Jan2021): New information from a contactable consumer (patient) includes: Reaction data (add event white blood count went really high, outcome of event extremely achy/body aches updated). This case has been upgraded to serious.
entire arm is numb and he cannot lift it up; This is a spontaneous report received from a contactable consumer from Pfizer Sponsored program. This consumer (patient's wife) reported for a male patient (reporter's husband) of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Lot number and Expiration date was not reported), via an unspecified route of administration on an unspecified date (time around 10:00) as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Reporter stated that her husband had the first dose of Pfizer's COVID vaccine on an unknown date around 10:00 and his "entire arm is numb and he cannot lift it up". Reporter was asking what you recommend for him. Reporter was reluctant to transfer as she stated she should had gone to the ER (emergency room) instead of calling. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained
Itching, chest tightness, SOB, tingling lips, loss of voice. Administered 100mg of benadryl within 5 min of symptom onset followed by Epi Pen with call to 911. Paramedics transported to ED. Patient was admitted with anaphylaxis.  Used Adverse Event  Emergency Policy.
mild circumoral cyanosis & very diaphoretic; placed on 02 then intubated; hypotensive & tachycardic to 202HR:
Hematuria (blood in urine), proteinuria, and abdominal pain approximately 20 hours after receiving influenza vaccine. Exam normal including blood pressure. Normal ASO, serum albumin, urine Ca/creatinine ratior, urine culture. Complement profile pending. Patient will have followup exam 1 week after incident.
A feeling of malaize approximately 12 hours after injection.  36 hours later, muscle pain in the upper inside of calf of lower left leg.  Pain in upper body joints and upper arm bones gradually increasing through first week after injection.  Almost exactly one week from injection, lower left leg and foot swell to approximately one and half normal size.  Doctor visit on eighth day and subsequent ultrasound to rule out blood clots.  Ceased all other meds and applied warm compresses to leg, elevated at night above heart...swelling reduced to approximately 10 to 20 percent above normal size.  Pain gradually reducing over time.  Still have swelling in late AM through PM, OK in early AM upon arising.  Still have joint and bone pain in upper body.  Intermittant feelings of malaize.
This spontaneous report was received from a licensed practical nurse concerning an unspecified number of patients of unknown age and unknown gender. The patients' medical history, concurrent conditions, concomitant therapies, drug reactions or allergies were not reported. On unspecified dates, starting on or after 01-SEP-2015, the unspecified patients were vaccinated with improperly stored doses of VAQTA, lot # L018499, expiration date 25-FEB-2017, (dose, dose number, route and anatomical location were unspecified). No adverse effect reported. This is one of several reports received from the same reporter. Additional information has been requested.
Developed red dots over total body 1.5-2weeks after receiving vaccines.  Red dots started on legs then moved to her stomach. Symptoms lasted one week.
I had a stuffy nose and I had to blow my nose, that's it. It lasted 7 days from the time it started till it ended. It was a 4/5 in level of severity. If my family hadn't tested their child and they came out positive I would never have thought to get tested for COVID. My allergies have been worse than this. Those 2 symptoms were all I had.
This case was reported by a healthcare professional and described the occurrence of vaccination complication in a 6-year-old female subject who was vaccinated with HAVRIX for prophylaxis. Previous and/or concurrent vaccination included FLUMIST; manufacturer unspecified given on 21 November 2008. On 21 November 2008 at 15:45, the subject received 2nd dose of HAVRIX (.5 ml, unknown, left arm). On 21 November 2008, at the time of vaccination with HAVRIX, the subject experienced vaccination complication and accidental blood exposure. The reported noticed when the administering nurse drew back the syringe prior to injecting HAVRIX there was blood in the vaccine (vaccine complication). The vaccine was given in this manner and no adverse events have been experienced. At the time of reporting the outcome of the events were unspecified.
Had redness, swelling within 4 hrs. Severe pain, redness & swelling by next A.M.(lasted 3 days). 24 hrs later had chills, body aches, sore joints, Temp of 100.4. 36 hrs later had diarrhea. 5 days later symptoms had subsided.
Spreading rash on lower left chest, pain in left back, noticeable beginning 05/25/2019.   Diagnosed 05/29/2019 by M.D. as shingles.  Treated with acyclovir 400mg 5 times per day for 7 days, beginning 05/29/2019.  Rash and pain persisting as of today (06/02/2019), with back pain making it hard to sleep.
I experienced fever, body chills, pain at the injection site. I also had a swollen lymph node under my armpit.  I also experienced hot flashes, chills which lasted for one week. I had discharge from my breasts and a diagnostic mammogram and bilateral  ultrasound of the breasts were performed, these exams were negative. My doctor thinks this symptom was from the vaccine.
Headache, Myalgia, Fever, Pain at injection site; then 1/5/2021, headache, weakness, fever; resolving today
got sick from the Prevnar 13; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a sponsored program. The reporter is the patient.  A 76 year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) (Batch/Lot number: unknown) as dose number unknown, single for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "got sick from the Prevnar 13". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Fever, temp of 103, muscle aches, fatigue, head ache. Lasted almost 24 hours.